BRAF and melanoma: A 3rd phase trial was directed on double-blind, randomized, placebo-controlled patients in 112 organizations in around 20 countries for cobimetinib, vemurafenib, and atezolizumab for advanced BRAF V600 mutation-positive unresectable melanoma as first-line treatment.